Category Archives: HIV cure advocacy

CROI 2017: The best HIV cure will be built with us, not just for us

Among the world’s top scientific conferences on HIV, the Conference on Retroviruses and Opportunistic Infections (CROI) stands among the most prestigious. Only a handful of the top submissions of new scientific data are deemed worthy of stage time. Submissions deemed less worthy are relegated to the…Read More

Generic HIV drugs will be a good thing right?

In 2017, the patents for two antiretroviral drugs for HIV that continue to be widely used will  likely expire in the United States and generic alternatives at lower market prices could be introduced. Some have long awaited this occurrence, hoping for increased competition and a drive…Read More

Glosario de la Investigacíon sobre la Cura para el VIH/SIDA y Guía de Recursos del 2016

Para informar mejor a los periodistas, trabajadores de servicios, promotores de salud y personas con VIH sobre los cambios en el campo de la investigación para la cura del VIH, los defensores de la Empresa Delaney de Investigación del SIDA (DARE), con la asistencia del colaboratorio…Read More

Project Inform: Transforming Hope into Reality

David Evans, Project Inform office circa 1993 When I started volunteering there in December 1992, Project Inform remained persistent in its message that you could take charge of your own health, all the while struggling against the pain of losing friends, lovers and family members to…Read More

HIV advocates publish HIV/AIDS Cure Research Glossary & Resource Guide

  To better inform journalists, service workers, advocates and people with HIV on the exciting and rapidly moving field of HIV cure research, advocates from the Delaney AIDS Research Enterprise (DARE), with assistance from advocates from the defeatHIV collaboratory and the Collaboratory of AIDS Researchers for…Read More

IAS2015: Teenager infected at birth controls HIV for 11 years without drugs

by David Evans, Director of Research Advocacy An HIV-positive teenager who started antiretroviral (ARV) drugs as an infant and stayed on them for about seven years, is now 18 years old and has been off of all medications for 11 years with very low levels of…Read More

CROI2015: New “Kick and Kill” HIV cure drug (TLR7 agonist) from Gilead shows promise

A new type of drug, called a toll-like receptor 7 (TLR7) agonist, was able to activate HIV-infected CD4 cells from HIV-positive donors on antiretroviral therapy (ART), leading to the release and replication of virus, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic…Read More